

Date: _____

Patient information

Patient name: _____

Patient address: _____

Patient Phone number: _____

Member ID: _____

Patient date of birth: _____

Allergies: No known allergies: _____Current weight: _____ lbs kg Height: _____**Primary diagnosis:**

Hemophilia type A factor VIII deficiency, D66
 Hemophilia type B factor IX deficiency, D67
 Hemophilia type C factor XI deficiency, D68.1
 von Willebrand disease, D68.0
 Other: _____

Clinical documents (please attach)

History and Physical (H and P) and progress notes within past six months

Severity: Mild Moderate Severe von WillebrandTarget joint(s): Yes No Location: _____Inhibitor: Yes No (Bethesda unit: _____)Venous access: Peripheral Port PICC→ number of lumens: _____Site of care: Patient's home Physician's office Outpatient infusion clinic: _____Self-infused? Yes No

Pharmacy will dispense ancillary supplies as needed to establish IV and administer prescription drug.

Prescriber signature: _____

Prescriber name: _____

Prescriber address: _____

DEA number: _____

NPI number: _____

Prescriber phone number: _____

Prescriber fax number: _____

Please provide supervising prescriber information (if applicable):

Prescriber name: _____

Prescriber address: _____

Prescriber phone number: _____

DEA number: _____

NPI number: _____

Note: If all information is not completed, the patient request will not be processed. We will contact your office for clarification.

Prescription information

<input type="checkbox"/> ADVATE®	<input type="checkbox"/> ADYNOVATE®	<input type="checkbox"/> AFSTYLA®
<input type="checkbox"/> ALHEMO® PEN	<input type="checkbox"/> ALPHANATE®	<input type="checkbox"/> ALPHANINE® SD
<input type="checkbox"/> ALPROLIX®	<input type="checkbox"/> ALTUVIIO®	<input type="checkbox"/> BENEFIX®
<input type="checkbox"/> ELOCTATE®	<input type="checkbox"/> FEIBA® VH	<input type="checkbox"/> FIBRYGA®
<input type="checkbox"/> HEMLIBRA®	<input type="checkbox"/> HUMATE-P®	<input type="checkbox"/> HYMPAVZI® PEN
<input type="checkbox"/> IDELVION®	<input type="checkbox"/> IXINITY®	<input type="checkbox"/> JIVI®
<input type="checkbox"/> KCENTRA®	<input type="checkbox"/> KOATE®	<input type="checkbox"/> KOVALTRY®
<input type="checkbox"/> NOVOEIGHT®	<input type="checkbox"/> NOVOSEVEN® RT	<input type="checkbox"/> PROFILNINE® SD
<input type="checkbox"/> REBINYN®	<input type="checkbox"/> RIXUBIS	<input type="checkbox"/> SEVENFACT®
<input type="checkbox"/> WILATE®	<input type="checkbox"/> XYNTHA®	
<input type="checkbox"/> Other: _____		

Prophylaxis dosing: _____

Number of doses: _____ Refill for one year or _____

On-demand/as-needed dosing: _____

Number of doses: _____ Refill for one year or _____

 Normal saline 10 mL IV flush syringe Directions: Use as directed to flush line with 10 mL before and after factor infusion and P.R.N. line care

Quantity: 28-day supply Refill for one year or _____

 heparin 100 units/mL 5 mL prefilled syringe Directions: Use as directed to flush line with 5 mL after final saline flush and P.R.N. line care

Quantity: 28-day supply Refill for one year or _____

Other therapies: DDAVP 4 mcg/mL injection Directions: _____

Quantity: _____ Refills: _____

 Amicar® 500 mg tablets 1,000 mg tablets 250 mg/mL syrup

Directions: _____

Quantity: _____ Refills: _____

 Lysteda® Directions: _____

Quantity: _____ Refills: _____

 lidocaine/prilocaine cream 2.5%-2.5%

Directions: Apply topically to needle insertion site 30-60 minutes prior to needle insertion as directed.

Quantity: 30 grams Refills: _____

 The skilled nursing visit will establish venous access, provide patient education related to therapy and disease state, administer medication as prescribed, and assess general status and response to therapy. Visit frequency is based on prescribed dosage orders.

You can send this prescription electronically (eRx) by selecting "CenterWell Specialty Pharmacy" (National Council for Prescription Drug Programs ID number 3677955) from the list of pharmacies on your e-prescribing tool.